A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Phase 1 Recruiting 30 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.

Timeline

Start: 2025-03-17
Primary completion: 2026-12-01
Completion: 2027-03-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VIS171	Unknown	—	Subcutaneous

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Summary

Timeline

Drugs

Indications